CETP Inhibitors Back In The Fold: Amgen Dives In With Dezima Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
TA-8995 is potentially best-in-class and could fill a void in Amgen's portfolio for an oral agent, Exec VP R&D Sean Harper says in an interview. Development will focus on LDL-C lowering, not HDL-C increases.